Search

Displaying results 2781 - 2790 of 8575 in total
  1. Drug

    Buserelin

    go.drugbank.com/drugs/DB06719
    ApprovedInvestigational

    Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.

  2. Drug

    Edotreotide gallium Ga-68

    go.drugbank.com/drugs/DB15494
    Approved

    [A185852] Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.[A185852] Edotreotide gallium Ga-68 was granted FDA approval on 21 August 2019.[L8597]

  3. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.

  4. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing.

  5. Drug

    Rindopepimut

    go.drugbank.com/drugs/DB05374
    Investigational

    Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant ...

  6. Drug

    Trapidil

    go.drugbank.com/drugs/DB09283
    Experimental

    Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney

  7. Drug

    Oxyphenonium

    go.drugbank.com/drugs/DB00219
    Approved

    It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem]

  8. Drug

    Diloxanide

    go.drugbank.com/drugs/DB08792
    Experimental

    Diloxanide (as [Diloxanide furoate]) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. … Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.

  9. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    [L10755,L10758] Golodirsen was initially rejected for FDA approval over concerns about its potential renal toxicity, however, clinical trials did not show significant toxicity.[L10755] … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of

  10. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    Since it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia. … PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.